Neil  Kumar net worth and biography

Neil Kumar Biography and Net Worth

Neil Kumar, Ph.D. is a co-founder and has served as our Chief Executive Officer and a member of our Board of Directors since April 2015. Dr. Kumar has also served as the Chief Executive Officer of our subsidiary, Eidos Therapeutics, Inc. (formerly Nasdaq: EIDX), a clinical-stage biopharmaceutical company, and a member of Eidos Therapeutics’ board of directors since March 2016. Prior to that, he served as the interim vice president of business development at MyoKardia, Inc. (formerly Nasdaq: MYOK, acquired by Bristol Myers Squibb), a clinical-stage biopharmaceutical company, from 2012 to 2014. Prior to that, Dr. Kumar served as a principal at Third Rock Ventures, a venture capital firm, from 2011 to 2014. Before joining Third Rock Ventures, he served as an associate principal at McKinsey & Company, a worldwide management consulting firm, from 2007 to 2011. Dr. Kumar has served as a member of the board of directors of LianBio (Nasdaq: LIAN) since October 2019. He received his B.S. and M.S. degrees in chemical engineering from Stanford University and received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology. Dr. Kumar’s qualifications to serve on our Board of Directors include his role as our principal executive officer and his extensive experience as an executive officer of biotechnology companies.

What is Neil Kumar's net worth?

The estimated net worth of Neil Kumar is at least $132.67 million as of August 19th, 2024. Dr. Kumar owns 4,897,443 shares of BridgeBio Pharma stock worth more than $132,671,731 as of November 9th. This net worth estimate does not reflect any other assets that Dr. Kumar may own. Additionally, Dr. Kumar receives a salary of $1,530,000.00 as CEO at BridgeBio Pharma. Learn More about Neil Kumar's net worth.

How old is Neil Kumar?

Dr. Kumar is currently 45 years old. There are 7 older executives and no younger executives at BridgeBio Pharma. Learn More on Neil Kumar's age.

What is Neil Kumar's salary?

As the CEO of BridgeBio Pharma, Inc., Dr. Kumar earns $1,530,000.00 per year. Learn More on Neil Kumar's salary.

How do I contact Neil Kumar?

The corporate mailing address for Dr. Kumar and other BridgeBio Pharma executives is 421 Kipling Street, Palo Alto CA, 94301. BridgeBio Pharma can also be reached via phone at (650) 391-9740. Learn More on Neil Kumar's contact information.

Has Neil Kumar been buying or selling shares of BridgeBio Pharma?

Neil Kumar has not been actively trading shares of BridgeBio Pharma over the course of the past ninety days. Most recently, Neil Kumar sold 27,389 shares of the business's stock in a transaction on Monday, August 19th. The shares were sold at an average price of $24.69, for a transaction totalling $676,234.41. Following the completion of the sale, the chief executive officer now directly owns 4,897,443 shares of the company's stock, valued at $120,917,867.67. Learn More on Neil Kumar's trading history.

Who are BridgeBio Pharma's active insiders?

BridgeBio Pharma's insider roster includes Douglas Dachille (Director), Ronald Daniels (Director), Neil Kumar (CEO), Frank McCormick (Director), Richard Scheller (Insider), Randal Scott (Director), Brian Stephenson (CFO), and Hannah Valantine (Director). Learn More on BridgeBio Pharma's active insiders.

Are insiders buying or selling shares of BridgeBio Pharma?

In the last year, insiders at the sold shares 8 times. They sold a total of 5,939,959 shares worth more than $154,639,343.91. The most recent insider tranaction occured on September, 13th when Major Shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares worth more than $149,350,000.00. Insiders at BridgeBio Pharma own 24.7% of the company. Learn More about insider trades at BridgeBio Pharma.

Information on this page was last updated on 9/13/2024.

Neil Kumar Insider Trading History at BridgeBio Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/19/2024Sell27,389$24.69$676,234.414,897,443View SEC Filing Icon  
8/17/2023Sell51,552$28.59$1,473,871.684,813,197View SEC Filing Icon  
5/17/2023Sell51,552$14.01$722,243.524,813,197View SEC Filing Icon  
4/5/2023Sell120,000$15.46$1,855,200.001,132,722View SEC Filing Icon  
3/3/2023Sell120,000$10.96$1,315,200.001,252,722View SEC Filing Icon  
2/17/2023Sell44,798$12.70$568,934.604,813,197View SEC Filing Icon  
2/3/2023Sell120,000$11.01$1,321,200.001,372,722View SEC Filing Icon  
1/5/2023Sell120,000$7.67$920,400.001,492,722View SEC Filing Icon  
11/17/2022Sell34,640$9.40$325,616.004,813,197View SEC Filing Icon  
8/3/2020Sell66,057$27.27$1,801,374.394,685,725View SEC Filing Icon  
7/1/2020Sell87,025$31.09$2,705,607.254,685,725View SEC Filing Icon  
6/3/2020Sell5,930$30.05$178,196.504,685,725View SEC Filing Icon  
5/5/2020Sell79,600$31.02$2,469,192.004,685,725View SEC Filing Icon  
4/7/2020Sell1,805$25.48$45,991.404,685,725View SEC Filing Icon  
4/3/2020Sell300$25.09$7,527.004,685,725View SEC Filing Icon  
4/1/2020Sell62,117$26.26$1,631,192.424,685,725View SEC Filing Icon  
2/5/2020Sell30,893$34.87$1,077,238.914,685,365View SEC Filing Icon  
See Full Table

Neil Kumar Buying and Selling Activity at BridgeBio Pharma

This chart shows Neil Kumar's buying and selling at BridgeBio Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BridgeBio Pharma Company Overview

BridgeBio Pharma logo
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $27.09
Low: $25.57
High: $27.27

50 Day Range

MA: $26.02
Low: $23.38
High: $31.30

2 Week Range

Now: $27.09
Low: $21.62
High: $44.32

Volume

1,732,684 shs

Average Volume

1,839,445 shs

Market Capitalization

$5.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09